Simcere Pharmaceutical Group Ltd - Company Profile
Powered by 
All the sales intelligence you need on Simcere Pharmaceutical Group Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Simcere Pharmaceutical Group Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Simcere Pharmaceutical Group Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Simcere Pharmaceutical Group Ltd (Simcere) is a pharmaceutical company that discovers, develops and markets branded generic and prescription pharmaceutical products. The company's pipeline products include endostar which treats thoracoabdominal effusions; SIM0270(SERD BM) targets breast cancer; TGRX-326 for non-small cell lung cancer; SIM0237 which targets non-muscle invasive bladder cancer; SIM0500 treats multiple myeloma; SIM0395 for glioblastoma; SIM0501, SIM0508, SIM0505, SIM0686, SIM0323, SIM0609, SIM0610, SIM0613, SIM0688, SIM0532 and SIM0512 targets solid tumors; among others. It also offers prescription products for therapeutic areas including oncology, neuroscience, autoimmune, cardiovascular, anti-infection and others. The company’s brands include ENZESHU, LOWVO, Endostar, JEPASO, Enlength, Enlitai, QUVIVQ, among others. Simcere is headquartered in Nanjing, Jiangsu, China.
Headquarters
China
Address
No. 699-18, Xuanwu Road, Xuanwu District, Nanjing, Jiangsu, 210042
Website
www.simcere.com
No of Employees
7,038
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2096 (HKG)
Revenue (2024)
$1.1B
16.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
86.2%
(2024 vs 2023)
Market Cap*
$3.9B
Net Profit Margin (2024)
XYZ
59.7%
(2024 vs 2023)
* As of and is in US$
Simcere Pharmaceutical Group Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Endostar |
| Endostar: Thoracoabdominal Effusions | Sanbexin |
| SIM0270: Breast Cancer | ENZESHU |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In August, the company received approval from the National Medical Products Administration for Cocelera (triasicillib hydrochloride for injection) for patients with recurrent extensive-stage small cell lung cancer. |
| 2026 | Contracts/Agreements | In August, the company partnered with Ruiyang Biopharmaceutical to obtain commercialization rights for culevibimab in China. |
| 2026 | Contracts/Agreements | In January, the company signed an agreement with Boehringer Ingelheim to develop Simcere’s preclinical TL1A/IL23p19 bispecific antibody SIM0709 for inflammatory bowel disease. |
Competitor Comparison
| Key Parameters | Simcere Pharmaceutical Group Ltd | Jiangsu Nhwa Pharmaceutical Co Ltd | Duality Biotherapeutics Inc | Shenzhen Chipscreen Biosciences Co Ltd | Qilu Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Nanjing | Xuzhou | Shanghai | Shenzhen | Jinan |
| State/Province | Jiangsu | Jiangsu | Shanghai | Guangdong | Shandong |
| No. of Employees | 7,038 | 6,003 | 231 | 1,002 | 38,000 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ren Jinsheng | Chairman | Executive Board | 2004 | 63 |
| Wan Yushan | Chief Financial Officer; Director; Joint Secretary | Executive Board | 2017 | 55 |
| Tang Renhong | Chairman - Simcere Zaiming; Chief Executive Officer - Simcere Zaiming; Director | Executive Board | 2022 | 46 |
| Wang Xi | Director; Vice President | Executive Board | 2023 | 43 |
| Zhou Yunshu | Chief Executive Officer | Senior Management | 2026 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer